Shionogi & Co., Ltd.

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-07-14 EDT			5-day change	1st Jan Change
2,487.50 ^JPY	+0.32%		+0.08%	+12.10%

09:01am	ViiV expands licence to allow generic HIV treatment production for low-income countries	RE
07-10	Shionogi & Co., Ltd. Implements Stibo Systems MDM Solution	CI

Shionogi & Co Ltd: Shionogi Submits Supplemental New Drug Application For Ensitrelvir In Japan For Post-Exposure Prophylaxis Of Covid-19

Published on 2025-03-26 at 23:30

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shionogi & Co., Ltd.

ViiV expands licence to allow generic HIV treatment production for low-income countries	09:01am	RE
Shionogi & Co., Ltd. Implements Stibo Systems MDM Solution	07-10	CI
Stallergenes Greer, Shionogi & Co., Ltd. and Ceolia Pharma Co. Ltd Announces the Transition of Promotional Activities for Actair®? in Japan	07-03	CI
Correction: BioVersys to Collaborate With Japan's Shionogi on Novel Ansamycin Leads	07-02	MT
BioVersys AG and Shionogi & Co., Ltd Enters into Global Research Collaboration for Broad-Spectrum Non-Tuberculous Mycobacteria Clinical Candidate	07-02	CI
BioVersys to Collaborate With Japan's Shionogi on Novel Ansamycin Leads	07-02	MT
Shionogi & Co., Ltd. Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Treatment of COVID-19 in Pediatric Patients Aged 6 Years and Older	06-30	CI
Shionogi Seeks Japan Approval to Expand COVID-19 Drug Ensitrelvir for Pediatric Use	06-30	MT
Shionogi Completes Tender Offer for Torii Pharmaceutical, Acquiring 39% Stake	06-18	MT
Shionogi & Co., Ltd. completed the acquisition of 44.1% stake in Torii Pharmaceutical Co., Ltd. from group of sellers.	06-17	CI
Japan Shares Fall as Tokyo Inflation Hits Two-Year High	05-30	MT
Shionogi & Co., Ltd. Announces Acceptance of New Drug Application for Naldemedine tosilate in China	05-30	CI
Shionogi's Opioid-Induced Constipation Drug Accepted for Review in China	05-30	MT
Shionogi & Co Ltd - Acceptance Of A New Drug Application For Naldemedine, A Treatment For Opioid-Induced Constipation, In China	05-29	RE
Shionogi & Co., Ltd. and Veritas in Silico Inc. Announce Milestone Achievement in Joint Drug Discovery Research of mRNA -Targeted Small Molecules	05-23	CI
Shionogi & Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2025 and for the Year Ending March 31, 2026	05-12	CI
Japan's Nikkei ends higher; NTT Data surges on takeover report	05-08	RE
Japan's Nikkei rises; NTT Data set to surge on takeover report	05-07	RE
Shionogi to Acquire Japan Tobacco's Pharma Business, Take Full Control of Torii Pharmaceutical	05-07	MT
Deals of the day-Mergers and acquisitions	05-07	RE
Deals of the day-Mergers and acquisitions	05-07	RE
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion	05-07	RE
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion	05-07	RE
Japan's Nikkei snaps 7-day winning streak as US tariff worries weigh	05-07	RE
Shionogi & Co: To Launch Tender Offer For Torii Pharmaceutical Shares At 6,350 Yen Per Share	05-07	RE

Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.

Employees

4,955

Sector

Pharmaceuticals

Calendar

07-27 - Q1 2025 Earnings Release

More about the company